

Date: May 15, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Sub.: Submission of Media Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Media Release in relation to the Audited Standalone and Consolidated financial results of the company for the quarter and financial year ended March 31, 2025 duly approved by the Board of Directors of the Company in their meeting held on May 15, 2025.

Please note that the Media Release enclosed herewith shall supersede the Media Release submitted along with outcome of Board Meeting held on May 15, 2025.

You are requested to take the same on your record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

SENORES PHARMACEUTICALS LIMITED

Strong Financial & Operational Performance for Q4 & FY25

Ahmedabad, Gujarat, 15th May 2025 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its audited Financial Results for the 4th Quarter of FY25 ended 31st March 2025.

Q4 & FY25 CONSOLIDATED FINANCIAL HIGHLIGHTS

Total Income*

Rs. 410 Crs

 **91%**

Y-o-Y for FY25

EBIDTA

Rs. 102 Crs

 **145%**

Y-o-Y for FY25


Profit before Tax (PBT)

Rs. 71 Crs


 **183%**

Y-o-Y for FY25


Total Income* (INR Crs)




EBITDA (INR Crs)




PBT (INR Crs)




Gross Margin (%)



EBITDA Margin (%)



PBT Margin (%)




* Total Income includes Revenue from Operations & Other Operating Income

Q4 & FY25 OPERATIONAL & FINANCIAL HIGHLIGHTS


Income Breakup

■ Regulated Markets ■ Emerging Markets ■ Others


Q4FY24




Q4FY25




FY24




FY25




Regulated Markets



Emerging Markets



Others



- For FY25, **Regulated Market** Revenue stood at Rs. 244.8 crs, a **growth of 69% on a Y-o-Y basis**. EBITDA for Regulated Market business stood at Rs. 101.9 crs, with EBITDA Margin of 38.4%.
- Emerging Markets** Revenue stood at Rs. 121.2 crs, a **growth of 174% on a Y-o-Y basis**. Emerging Markets EBITDA Margin stood at 7.0% for FY25.
- In the regulated markets currently, company has;
 - 22 Own commercial products
 - 61 Approved ANDA products
 - 51 Pipeline products with 28 CGT opportunity products
 - 22 CDMO/CMO commercial products
 - 69 CDMO/CMO pipeline products
- For the emerging markets currently, company has;
 - 285 Approved products
 - 636 products under registration
 - Presence across more than 40 countries

Commenting on the results, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

*“We are pleased to report strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our **Total Income** and **Profit before Tax** for FY25 have increased by **91% & 183% respectively** on year-on-year basis, and we are optimistic about sustaining this momentum going forward.*

We continued to make steady progress on our stated strategies. During the quarter, we expanded our portfolio in the Regulated Markets through acquisition of 14 ANDA's from Dr. Reddy's and 1 ANDA from Breckenridge Pharmaceuticals. A large part of this acquired ANDA basket has considerable government contract opportunities. Further, our CDMO/CMO segment is gaining traction and continued to scale up well. We have launched 1 new product in the CDMO/CMO segment during the quarter and have 69 products in pipeline.

Our shift in product portfolio and go-to-market strategies in the Emerging Markets business is beginning to give the desired results, which can be seen in the improvement in margin during the quarter. We have registered 48 new products across the Emerging Markets during Q4FY25, taking the total portfolio to 285 registered products.

Going forward, although the uncertainties due to the tariff situation in USA will have to be closely monitored, we believe we are well placed to navigate the same, given our USFDA-approved manufacturing facility in USA.

We will continue to focus on three key pillars going forward – Expansion of ANDA portfolio in Regulated Markets; Steady scale-up of CDMO/CMO segment in the Regulated Markets; and Portfolio expansion and profitability improvement in the Emerging Markets.”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 280 product registrations and over 630 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899